EBC-46

Botany

Canopy Density and Fruit Yield in Fontainea picrosperma: Light-Microclimate Effects

How canopy structure modulates the light microclimate around Fontainea picrosperma trees and what that means for fruit set, seed development, and cultivation planning.

Human Trials

Open-Label vs. Randomised Designs in Tigilanol Tiglate Trials: Methodological Trade-Offs

A neutral comparison of open-label and randomised study designs used in the tigilanol tiglate clinical programme, and what each design choice can and cannot demonstrate.

Mechanism of Action

MAPK Signalling Cascade: How Tigilanol Tiglate Engages Cellular Stress Response Pathways

A focused look at how tigilanol tiglate (EBC-46) engages the MAPK family — ERK, JNK, and p38 — to amplify localised stress signalling within tumour tissue during preclinical experiments.

Regulatory

Brazil ANVISA Botanical Medicine Framework: How EBC-46 Supplements Are Classified

A neutral overview of how Brazil's ANVISA classifies botanical products and how EBC-46 / blushwood berry supplements would fit within the country's tiered regulatory pathways.

Consumer Reports

EBC-46 Supplement Timing With Other Botanicals: User Reports on Stack Compatibility

Aggregated user reports on how readers schedule blushwood berry extract alongside other botanicals — timing patterns, perceived tolerability, and practical notes.

Natural Source

Shade Tolerance and Light Requirements in Fontainea picrosperma: Cultivating the Blushwood Berry

Fontainea picrosperma is a rainforest understorey species with specific photosynthetic light demands. Implications for cultivation and consistent EBC-46 yield.

Human Trials

CTCAE Adverse Event Grading in Tigilanol Tiglate Trials: How EBC-46 Clinical Safety Is Measured

CTCAE v5.0 framework explained — how Common Terminology Criteria for Adverse Events grade severity in tigilanol tiglate (EBC-46) clinical trials.

Mechanism of Action

Immunogenic Cell Death and DAMPs: How EBC-46 (Tigilanol Tiglate) Recruits the Immune System Against Tumours

How EBC-46 / tigilanol tiglate triggers immunogenic cell death and releases damage-associated molecular patterns to recruit innate and adaptive anti-tumour immunity.

Regulatory

Health Canada NHPD: How EBC-46 Botanical Supplements Are Classified Under Canadian Natural Health Product Regulations

Examining how Canadian Natural Health Product regulations under Health Canada's NHPD classify blushwood berry extract supplements containing EBC-46.

consumer

Capsule Swallowing Experience for EBC-46 Supplements: A User-Reports Overview

What consumers report about swallowing EBC-46 capsules — size, coating, water needs, and how routines compare with the tincture format.

Botany

Genetic Diversity in Fontainea picrosperma: Population Genetics and Conservation of the Blushwood Tree

What molecular surveys reveal about genetic diversity within wild Fontainea picrosperma populations, and why the tree's narrow range matters for EBC-46 source botany.

trials

Quality-of-Life Endpoints in Tigilanol Tiglate Trials: How Patient-Reported Outcomes Are Measured

How tigilanol tiglate clinical trials capture patient-reported quality-of-life data, what instruments are used, and how QoL fits alongside tumour-response endpoints.